Impact of new treatment options for hepatitis C virus infection in liver transplantation

Table 2 Sustained virological response among recent clinical trials of new treatment regimens for hepatitis C virus including patients with cirrhosis

Ref.	Trial	Population	Drug	Overall SVR12	SVR12 in cirrhosis
Jacobson et al[143], 2014	Fusion	G2, G3 experienced	SOF/RBV 12 vs 16 wk	G2 86% vs 94%	G2 60% vs 78%
		34% cirrhotic		G3 62% vs 30%	G3 19% vs 61%
Lawitz et al[33], 2015	Fission	G2, G3 naïve	SOF/RBV 12 wk vs Peg-IFN/RBV 24 wk	G2 97% vs 78%	G2 92% vs 62%
		20% cirrhosis		G3 56% vs 63%	G3 30% vs 34%
Jacobson et al[143], 2014	Positron	G2, G3 naïve and experienced IFN ineligible	SOF/RBV	G2 93%, G3 61%	G2 92%, G3 21%
Zeuzem et al[144], 2014	Valence	G3 extended 24 wk 21% cirrhosis	SOF/RBV	G2 94%, G3 91%	G2 82%, G3 68%
Lawitz et al[42], 2015	Lonestar-2	G 2 and 3	SOF/RBV/Peg-IFN	G2 96%, G3 83%	G2 93%, G3 83%
Bourliere et al[43], 2015	Sirius	G1 with compensated cirrhosis, NR previous treatment	SOF/LDV 24 wk vs SOF/LDV/RBV 12 wk	N/A	97% vs 96%
Lawitz et al[36], 2014	Cosmos	G1 NR, 52% F3-F4	SOF/SMV ± RBV 12 or 24 wk	92%	94%
Gane et al[114], 2014	Electron II	G1 naïve, experienced and decompensated, G3 naïve, 15% cirrhosis	LDV/RBV 12 wk	G1 100%, G3 64%	G1 65%

Peg-IFN: Pegylated interferon; RBV: Ribavirin; SVR12: Sustained virological response; G: Genotype; LDV: Ledipasvir; SOF: Sofosbuvir; SMV: Simeprevir; NR: Non responder.